glp 1 weight loss maintenance after discontinuation of GLP-1 therapies TrimRX | How to Adjust

Orforglipron met ATTAIN-1s primary endpoint by lowering weight by an average of 12.4% (27.3 lbs) vs

In 2009, the JDRF developed an artificial pancreas road map defining 6 stages of APDS technology based on the level of automation (59): First generation Stage 1: Very-Low-Glucose Insulin Off Pump

The support of telehealth appointments to ensure continuous care and monitoring

Because innovation without access, and science without literacy, never changes public health

In summary, while a meta-analysis of these trials could yield valuable insights into the class effect of GLP-1 receptor agonists on OSA severity in populations with obesity (with or without T2DM), caution must be exercised in interpreting pooled results due to heterogeneity in population, intervention, and background therapy

When fatigue occurs in patients taking GLP-1 receptor agonists, it may be directly related to the medication, secondary to the physiological changes these drugs induce (such as reduced caloric intake or altered glucose metabolism), or entirely unrelated to the treatment